Why the study?
Does proteomic analysis help discover early biomarkers for predicting diabetic microvascular and macrovascular complications?
Does proteomic analysis help discover early biomarkers for predicting diabetic microvascular and macrovascular complications?
Proteomics is a promising tool for discovering early biomarkers to predict and understand diabetic microvascular and macrovascular complications.
Supports proteomic biomarker exploration in diabetes; leaves open prospective validation before clinical adoption.
BACKGROUND: The incidence of diabetes is increasing rapidly, owing to unhealthy lifestyles. The human suffering and healthcare burden caused by diabetes are mainly a consequence of its microvascular and macrovascular complications. Late diagnosis and lack of strict metabolic control lead to increased morbidity and mortality. A problem is the insidious course of the complications, diagnosed in advanced stages, when end organ damage is already present. OBJECTIVE: Discovery of early markers of microangiopathy and macroangiopathy may help to identify patients at risk of organ damage. METHODS: This review focuses on recent developments in proteomics, performed on body fluids and different tissues implicated in microvascular and macrovascular complications. RESULTS: The results provide important information for the early detection of diabetic complications as well as for better understanding of their pathophysiology.
No takes yet. Share an insight, caveat, or question.
Maris et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: